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Fig. 1. The chemical structures of dFdC, dFdU and internal standard.
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Fig. 2. Metabolism of gemcitabine.

dosing regimens, both normal-phase and reversed-phase
liquid chromatography with ultraviolet detection (LC-UV)
methods have been developed [5–8].
A Phase I trial of weekly dFdC given as 24-h infusion followed by a 24-h infusion of 5 -fluoro-2 -deoxyuridine (floxuridine, FUDR® , Roche Laboratories, Nutley, NJ, USA) and
oral calcium leucovorin was conducted in our clinic. This
trial was implemented based on the following considerations: (a) the efficacy of dFdC is schedule dependent and
continuous infusion is more effective than bolus injection in
xenograft models [9]; (b) our studies showed that the administration of dFdC followed by 5-FU led to more than additive
cytotoxicity and enhanced DNA damage in a human colon
cancer cell line [10]; (c) the pharmacologic data revealed
that dFdC has a very short half-life (median 8 min in one
study) [7,8]; and (d) the conversion of dFdC to dFdCMP is
saturable [11,12]. To ensure the tolerability of dFdC, patients
received an initial cycle of dFdC as 24 h infusion weekly for
3 weeks out of four. A prior Phase II study of dFdC given
as weekly 24-h infusion suggested that 180 mg/m2 was the
maximum tolerated dose [12]; the starting dose for our trial
was 150 mg/m2 . If tolerated, FUDR and oral calcium leucovorin were added to the subsequent cycle.
Because the plasma concentrations of dFdC in the 24-h
infusion study were anticipated to be below or near the limits of quantitation of the liquid chromatography (LC)-UV

methods, a more sensitive and specific analytical method
was therefore needed. This work describes the development
and validation of a liquid chromatography/mass spectrometry (LC-MS) method for the determination of dFdC and
its deaminated metabolite dFdU in human plasma at low
concentrations.

Experimental
Chemicals and solutions
Gemcitabine (dFdC) was supplied by the Cancer Therapy Evaluation Program at the National Cancer Institute
(Bethesda, MD, USA). It was formulated by Eli Lilly as
a lyophilized product containing the equivalent of 200 or
1000 mg gemcitabine (LY188011) as the hydrochloride
salt. 2 ,2 -Difluoro-2 -deoxyuridine (dFdU) was provided
by Lilly Research Laboratories (Indianapolis, IN, USA)
through a material transfer agreement with the National Cancer Institute. The internal standard, 5 -deoxy-5-fluorouridine
(5 -DFUR), was obtained from Sigma (St. Louis, MO,
USA). Ammonium acetate was from Aldrich (Milwaukee,
WI, USA). HPLC grade water and methanol were from
Fisher (Fair Lawn, NJ, USA). Tetrahydrouridine (Lot No.
112907-J/22) was provided by the Drug Synthesis and
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Chemistry Branch at the National Cancer Institute. Pooled
donor plasma was provided by the Department of Transfusion Medicine, Warren G. Magnusen Clinical Center,
National Institutes of Health (Bethesda, MD, USA).
A stock solution of ammonium acetate (100 mM, pH 6.8)
was prepared by dissolving appropriate amounts of ammonium acetate in a known volume of HPLC grade water. Five
millimolar ammonium acetate at pH 6.8 was prepared by
1:20 dilution of the stock solution with HPLC grade water.
Standard stock solutions of dFdC and dFdU (10.0 mg/ml),
and the internal standard stock solution of 5 -DFCR
(500 g/ml) were prepared by dissolving appropriate
amounts of compounds in known volumes of methanol.
Standard mixture working solutions of dFdC and dFdU at
the concentrations of 0.0500, 0.100, 0.500, 1.00, 5.00, 10.0,
20.0 and 50.0 g/ml were prepared by mixing and serial
dilutions of the stock solutions with methanol. The internal
standard working solution (5.00 g/ml) was prepared by
100-fold dilution of the stock solution with methanol.
Blank plasma, plasma standards and patient samples
Pooled donor plasma containing 1 M tetrahydrouridine
was used as the blank plasma in this study. To prepare
plasma standards, 50 l of standard mixture working solutions of dFdC and dFdU at each concentration level and
50 l of internal standard solution (5 -DFUR, 5.00 g/ml)
were added to 1.5-ml centrifuge tubes (Marsh Bio Products
Inc., Rochester, NY, USA). After the solutions were dried at
30 ◦ C for 20 min in an Eppendorf VacufugeTM (Brinkmann
Instruments, Westbury, NY, USA), 500 l of blank plasma
was added to each tube. The resultant plasma standards
(dFdC and dFdU) were at the concentrations of 5.00, 10.0,
50.0, 100, 500, 1000, 2000 and 5000 ng/ml with a fixed concentration of internal standard 5 -DFUR (500 ng/ml).
To prepare patient plasma samples, aliquots of 50-l internal standard solution (5 -DFUR, 5.00 g/ml) were added
to 1.5-ml centrifuge tubes. After the solutions were dried at
30 ◦ C for 20 min in the Eppendorf VacufugeTM , 500 l of
patient plasma was added to each tube.
The above blank plasma, plasma standards, and patient
samples were subjected to solid phase extraction prior to the
instrumental analysis.
Solid phase extraction
Oasis® HLB (3 cm3 ) solid phase extraction cartridges
(Waters Corporation, Milford, MA, USA) were used for
sample preparation. A 500 l plasma sample containing
250 ng of internal standard was first diluted with an equal
volume of calcium- and magnesium-free phosphate buffered
saline (PBS, 1×, pH 7.4) (Invitrogen/Gibco, Grand Island,
NY, USA). The Oasis® HLB cartridge was conditioned
with 3 ml methanol and then 3 ml PBS. After loading the
sample, the cartridge was washed with 2 ml PBS and dried
with air. The analytes were eluted from the cartridge with

2 ml methanol. The eluate was collected in a glass tube
(12 mm × 75 mm) and dried in the Eppendorf VacufugeTM
at 30 ◦ C for 2 h. The residue was reconstituted in 500 l
HPLC-grade water and re-suspended. Reconsitution of
the residue was carried out in 37 ◦ C water bath for 5 min
to insure complete hydration. After filtering with a GHP
Acrodisc® syringe filter (0.45 m × 13 mm) (Pall Gelman
Laboratory, Ann Arbor, MI, USA), the solution was transferred to an autosampler vial (Waters, Part No. 186000326)
for the instrumental analysis.
Instrumentation
The instrumentation system consisted of a Waters 2690
separations module, a Micromass Platform LC mass spectrometric detector (electrospray ionization mode (ESI)-MS)
(Waters, Milford, MA, USA), and a personal computer station with MassLynx NT (Version 3.4) software (Micromass,
Manchester, UK). The analytical column was a Waters
YMC ODS-AQTM (5 m, 120 Å, 2.0 mm × 150 mm, Part #
AQ12S051502WT) column, which was preceded by a SecurityGuard guard column (Part # KJO-4282) (Phenomenex,
Torrance, CA, USA). The eluate from the analytical column
was diverted to the ESI-MS and to the waste via a PEEK
microvolume connector (Cat. # MT1XCPK) (Valco Instruments, Houston, TX) with a post-column split ratio of 1:2.
The smaller flow went to the ESI-MS and the larger one
to the waste. High pressure PEEK tubing was used for all
connections. The tubing prior to the inlet of the analytical
column was 1/16 in. o.d. and 0.01 in. i.d., and the tubing after the analytical column was 1/16 in. o.d. and 0.005 in. i.d.
Chromatographic conditions
The Waters 2960 separations module were operated under the following conditions: sample temperature, 4 (±1)
◦ C; analytical column temperature, 30 (±10) ◦ C; sample injection volume, 50 l. A gradient elution method was used
with two solvents: solvent A was 5 mM ammonium acetate
at pH 6.8 and solvent B was HPLC-grade methanol. The initial composition of the mobile phase was 98% solvent A/2%
solvent B (v/v). An isocratic gradient was used at 0.2 ml/min
for 3 min, followed by a linear gradient over 4 min to 70%
solvent A/30% solvent B. The gradient returned to the initial conditions by a linear gradient over 2 min and remained
there for 6 min prior to the next injection. The analytical column was equilibrated with the initial separation conditions
prior to the initial injection. The total run time for a LC-MS
analysis was 15 min per sample.
ESI-MS detection
The mass spectrometer was operated in the negative electrospray ionization mode. It was tuned by the infusion of
an analyte mixture (100.0 g/ml each in 5 mM ammonium
acetate, pH 6.8) with a Harvard syringe pump (Harvard
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Apparatus, South Natick, MA, USA, Cat. No. 55–1111)
at flow rate of 5.0 l/min via a 0.005 in. i.d. PEEK tubing. The tuning sample was converged with the incoming
LC mobile phase (98% of 5 mM ammonium acetate at pH
6.8 + 2% methanol at a flow rate of 0.2 ml/min before the
post-column split) in a sample tee prior to the MS detection. The optimized ionization conditions were: analytical
vacuum, <1.0 × 10−4 mbar; nitrogen gas, 400 l/h; capillary,
3.00 kV; cone, −25 V (dFdC and dFdU), −35 V (5 -DFUR);
ion source temperature, 140 ◦ C; low- and high-mass resolution, 15.0; ion energy, 0.8 V; and multiplier, −650 V.
Full-scan spectra were acquired in the continuum mode
over the mass range of 230–270 amu at a scan rate 200 amu/s.
Single-ion-monitoring (SIM) mode was used for analyte
quantitation by simultaneously monitoring quasi-molecular
ions, m/z 245 for [5 -DFUR–H]− , m/z 262 for [dFdC–H]− ,
and m/z 263 for [dFdU–H]− . Data acquisition was carried
out with a dwell time of 0.50 s, a span of 0.00 Da, a repeat
of 1, and an inter channel delay of 0.05 s. The cone voltages
were 35, 25, and 25 for m/z 245, 262, and 263, respectively.
Data analysis
Micromass MassLynx NT (Version 3.4) software was used
for acquisition of the LC-MS data, construction of the internal calibration curves, and derivation of the regression equations. The dFdC and dFdU concentrations in plasma samples
were determined by the regression equations after obtaining
the peak area ratios of the unknowns to the internal standard
from their mass chromatograms.
The area under the curve (AUC) was determined by
non-compartmental methods using a continuous intravenous
infusion model with WinNonLinTM (Version 4.0) (Pharsight Corp., Mountain View, CA, USA). Clearance was
calculated by dividing the dose rate by the steady-state.
Method validation
The recoveries were determined by comparing mean
peak areas of the plasma samples prepared by spiking the
blank plasma with known concentrations of dFdC, dFdU
and 5 -DFUR to the mean the peak areas of the control
samples prepared by spiking dFdC, dFdU and 5 -DFUR at
the same levels in 5 mM ammonium acetate solution (pH
6.8). The intra- and inter-assay precisions were determined
by analyzing the plasma samples with known concentrations of dFdC and dFdU within run and from different runs.
The linearities of the calibration curves were assessed by
the correlation coefficients. The limits of quantitation were
calculated by 10 times of signal-to-noise ratio.
Patient blood sampling
Eight adult patients with advanced cancer were enrolled in
an Institutional Review Board-approved Phase I trial involving dFdC as 24-h infusion weekly for three of 4 weeks. All

patients provided written, informed consent. Blood samples
were collected prior to (0 h) the infusion and at the steady
state during the infusion (22- and 23-h) in 10-ml green-top
heparinized Vacutainer® tubes (Becton Dickinson and Company, Franklin Lakes, NJ, USA) containing 10 nmol tetrahydrouridine as a cytidine deaminase inhibitor. The samples
tubes were immediately placed on ice and centrifuged for
10 min at 800 g (4 ◦ C). The plasma was then transferred into
three labeled Nalgene® cryogenic vials (Nalge Nunc International, Rochester, NY, USA) and stored at −70 ◦ C until
analysis.

Results and discussion
ESI-MS detection
Fig. 3 shows the full-scan ESI mass spectra of dFdC, dFdU
and internal standard 5 -DFUR, which indicated that detection of these compounds could be achieved by monitoring
quasi-molecular ions [dFdC–H]− at m/z 262, [dFdU–H]− at
m/z 263, and [5 -DFUR–H]− at m/z 245. Hence, these ions
were selected for SIM detection in the subsequent quantitative analysis. Although, the difference of m/z between
[dFdC–H]− and [dFdU–H]− was only by 1, the specificity of
the method could be further secured by choosing the proper
chromatographic conditions.
Chromatographic conditions
A YMC ODS-AQTM reversed-phase column and a gradient elution method were used for the separation of dFdC,
dFdU and 5 -DFUR in human plasma. As shown in our previous studies [13], the column is well suited for the separation of nucleosides. In the current study, dFdC, dFdU and
5 -DFUR were completely resolved from each other and
from endogenous compounds by the YMC ODS-AQTM column with retention times of 11.46, 12.63 and 13.58 min,
respectively (Fig. 4).
Solid phase extraction and recovery of analytes
We had previously reported that liquid–liquid extraction
with two sequential acetonitrile applications yielded the recovery of ≥70.0% for dFdC, and ≥81.8% for dFdU [6]. To
simplify the procedure, the Waters polymer-based Oasis®
HLB (3 cm3 ) extraction cartridge was evaluated for plasma
sample preparation. Using this preparatory method, the
absolute recoveries of dFdC, dFdU and internal standard
5 -DFUR from human plasma were found to be ≥86.8, 82.2
and 97.5%, respectively (Table 1), and the recovery data
were rather consistent throughout the concentration range
studied (50.0, 500, 5000 ng/ml). As compared with our
liquid–liquid extraction procedure, the solid-phase extraction with Oasis® HLB cartridge is simple, easy to handle,
and highly reproducible.
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Fig. 3. The full-scan mass spectra of dFdC, dFdU and 5 -DFUR (I.S.). Experimental conditions were described in Section 2.6.
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Fig. 4. Representative SIM chromatograms of dFdC, dFdU and 5 -DFUR in human plasma. Experimental conditions were described in Sections 2.5 and
2.6. Analyte concentration: 500 ng/ml.

3.4. Intra- and inter-assay precision
Table 1
Recovery of dFdC, dFdU and I.S. in human plasma (n = 3)
Analyte 50 (ng/ml)

500 (ng/ml)

5000 (ng/ml)

% Recovery %CV % Recovery %CV % Recovery %CV
dFdC
dFdU
I.S.a
a

89.0
84.6
102

7
1
1

89.4
82.2
98.3

2
2
3

86.8
86.9
97.5

I.S. (5 -DFUR) is at the fixed concentration of 500 ng/ml.

0.5
0.6
6

The intra- and inter-assay precisions of the method were
determined by analyzing blank plasma samples spiked
with known concentrations of dFdC and dFdU (50.0, 500,
5000 ng/ml). Three replicates were analyzed at each concentration level within a single run and from runs performed
on three different days. The results for dFdC and dFdU, as
well as 5 -DFUR, in human plasma were shown in Table 2.
The percent coefficients of variation (%CVs) for dFdC,
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Table 2
The intra-and inter-assay precision of plasma samples (n = 3)
Analyte

50.0 (ng/ml)

500 (ng/ml)

5000 (ng/ml)

Peak area

S.D.

%CV

Peak area

S.D.

%CV

Peak area

S.D.

%CV

Intra-assay
dFdC
dFdU
I.S.a

11173
42502
117098

31
412
1064

0.3
1
0.9

103912
313349
109613

1742
2769
3723

2
0.9
3

900129
1952863
125194

2677
12551
626

0.3
0.6
0.5

Inter-assay
dFdC
dFdU
I.S.a

12101
42394
118517

796
403
1605

7
1
1

103394
310931
113374

2059
5813
2912

2
2
3

892685
1950760
125538

4512
11800
700

0.5
0.6
6

a

I.S. (5 -DFUR) is at the fixed concentration of 500 ng/ml.

dFdU and 5 -DFUR were ≤3% for the intra-assay analyses
and ≤7% for the inter-assay analyses.
Linear calibration range
The linear relationships were found between the peak-area
ratios of dFdC and dFdU to internal standard 5 -DFUR
over the concentration range 5–1000 ng/ml for dFdC, and
5–5000 ng/ml for dFdU. The typical regression equations
were Y = (0.001815)X − 0.000311 for dFdC, and Y =
(0.004306)X + 0.033209 for dFdU with correlation coefficients ≥0.998 for both dFdC and dFdU.
Sensitivity and limits of quantitation
Fig. 5 shows the detection sensitivity during SIM for dFdC
and dFdU. The signal-to-noise ratio by root mean square
for 0.5 ng dFdC and dFdU were equal to 32 and 74. The
limits of quantitation were 3.16 ng/ml for plasma dFdC and
1.35 ng/ml for plasma dFdU with 50-l sample injections.
These limits of quantitation were at least 15–37 times lower
than those of the LC-UV methods [5,6].
Clinical and pharmacokinetic results
The validated assay was used to determine plasma concentrations of dFdC and dFdU in a Phase I trial of weekly
dFdC given as 24-h infusion followed by 24-h infusion of

FUDR. The first three patients received a starting dose of
150 mg/m2 dFdC. As none of these patients could tolerate
more than two weekly doses due to grade 2 mucositis and
grade 3 fatigue (one patient) or grade 3 thrombocytopenia
(two patients), the dose was decreased to 100 mg/m2 . At the
lower dose, one patient withdrew from the study after receiving a single dose for personal reasons; another patient
experienced small bowel obstruction due to tumor requiring surgical bypass and received only one dose. One patient experienced grade 4 neutropenia after two doses of
dFdC, but tolerated the subsequent cycle at a reduced dose
of 60 mg/m2 . Two patients received all three weekly doses,
but experienced grade 3 neutropenia that required a dose reduction to 80 mg/m2 for the second cycle. The toxicity observed with the 24-h infusion was felt to be prohibitive, and
this schedule was abandoned.
The pharmacokinetic parameters of dFdC and dFdU from
eight patients receiving their initial 24-h dFdC infusion are
summarized in Table 3. There were no significant differences
on the average plasma concentrations (Cp ) between the values of 22- and 23-h infusion, which were consistent with
achievement of steady-state concentrations. The average Cp
for dFdC during cycle one for 150 and 100 mg/(m2 24 h)
were 18.3 and 16.8 ng/ml, respectively, while the average Cp
for dFdU were 2950 and 1372 ng/ml. The ratios of dFdU to
dFdC in the 24-h dFdC infusion study were much greater
than those we previously determined with shorter infusion
times of 1- and 2-h [6]. The area under the curve (AUClast )

Table 3
The pharmacokinetic parameters of dFdC and dFdU during initial gemcitabine infusion
Gemcitabine
(mg/(m2 24 h))

Patients Average ± S.D.
AUClast (g/(ml min))

Cp (ng/ml)

dFdC

dFdC

dFdU

22 h

Ratio dFdU to

Median clearance
(ml/(min m2 ))

dFdU
23 h

150

3

12.1 ± 2.9 2020 ± 399 19.9 ± 4.4 16.7 ± 4.7

100

5

10.3 ± 5.8

a

dFdCa

22 h

23 h

2845 ± 558 3055 ± 781 160.9 ± 11.5

916 ± 333 16.0 ± 9.0 17.6 ± 10.4 1266 ± 438 1477 ± 590 128.0 ± 90.9

The 22- and 23-h values for dFdC and dFdU were averaged before calculating the ratio.

5961 (25%, 3988;
75%, 8703)
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Fig. 5. The SIM chromatograms of blank plasma and plasma spiked with known concentrations of dFdC and dFdU. Experimental conditions were the
same as in Fig. 4. Analyte concentration: 10 ng/ml; injection volume 50 l; 0.5 ng injected.

at dose levels of 150 and 100 mg/(m2 24 h) were 12.1 and
10.3 g/(ml min) for dFdC, and 2020 and 916 g/(ml min)
for dFdU. The medium clearance was 5961 ml/(min m2 ).

Conclusions
An LC-MS method has been developed and validated for
the determination of dFdC and dFdU at low concentrations in
human plasma. This method uses solid-phase extraction for
plasma sample preparation, reversed-phase LC for analyte
separation, and electrospray ionization mass spectrometry

for analyte quantitation. It employs an internal standard for
calibration and offers shorter chromatographic separation
time (15 min), and improved limits of quantitation for plasma
dFdC and dFdU. This method has been proven useful in a
Phase I trial of weekly dFdC given as 24-h infusion, where
the concentrations of dFdC were lower than or near the limits
of quantitation of the LC-UV methods. Although we do not
recommend further evaluation of the 24-h infusion schedule
of gemcitabine, this LC-MS method offers advantages over
the LC-UV methods in terms of shorter run times and greater
sensitivity, and may prove useful in the analysis of limited
volume biological samples and tissue pharmacokinetics.
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